Your session is about to expire
← Back to Search
Immunotherapy + Radiotherapy for Lung Cancer (SCION Trial)
SCION Trial Summary
This trial is testing a new immunotherapy drug to see if it's effective and safe to use with standard radiation treatment for early stage non-small cell lung cancer. If successful, this could become a new standard of care.
SCION Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSCION Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 2 trial • 20 Patients • NCT00350142SCION Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for at least 12 more weeks.I am post-menopausal or have a negative pregnancy test if pre-menopausal.I haven't taken immunosuppressive drugs in the last 14 days.Your recent lab tests must show that your organs are working well before starting the treatment.I have had cancer before, but it fits the exceptions.I can take care of myself and perform daily activities.My body weight is over 30kg.I don't have lasting side effects from cancer treatment, except for hair loss or skin changes.I am not pregnant or breastfeeding and willing to use birth control during and up to 90 days after treatment.I have not received a live vaccine in the last 30 days.I have previously been treated with specific immune therapies.I cannot undergo surgery for my condition, or I chose not to have surgery after a surgical evaluation.I have or had an autoimmune or inflammatory disorder.I have been diagnosed with non-small cell lung cancer.My lung cancer is early stage, small, and hasn't spread to lymph nodes or other parts.I have not had, nor am I planning to have, chemotherapy.You have had a serious problem with your immune system in the past.I am over 18, can make my own decisions, and agree to follow study rules.My cancer can't be clearly seen on a CT scan because of nearby lung issues.You have had an organ transplant from another person.I do not have active infections like TB, hepatitis B, C, or HIV.I am willing and able to follow the study's treatment plan and attend all visits.My lung tumor is located either centrally or peripherally.
- Group 1: MRD Negative
- Group 2: MRD Positive, no further therapy
- Group 3: MRD Positive, consolidation durvalumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has enrollment in this experiment commenced yet?
"The data available on clinicaltrials.gov indicates that this research initiative is not currently searching for participants, despite having been posted in June 2021 and updated with recent information the month after. Nevertheless, there are numerous other studies recruiting patients as of now."
Has Stereotactic Body Radiotherapy been authorized by the FDA?
"The safety of Stereotactic Body Radiotherapy was estimated by our team to be a 2, as there are some data in support of its security but no evidence demonstrating efficacy."
How many participants are being administered the treatment within this research study?
"This trial is not presently accepting participants, with the first post date being June 1st 2021 and last update occurring on the 24th of the same month. Should you be searching for other options, there are 4,424 studies currently recruiting patients diagnosed with carcinoma non-small cell lung cancer as well 333 trials actively enlisting subjects for stereotactic body radiotherapy."
What is the geographic dispersion of this clinical trial?
"Currently, this research project is accepting participants from 5 distinct sites. The cities of Victoria, Hamilton and Kelowna are all hosting these trials, along with an additional five locations. It would be prudent to choose the facility closest to you in order to minimize the need for travel when participating."
Can you elaborate on the existing research into Stereotactic Body Radiotherapy?
"Stereotactic Body Radiotherapy first emerged in 2010 at City of Hope, a renowned medical centre located in California. Subsequently, there have been 112 successful investigations and 333 ongoing trials mostly being conducted out of Victoria, Canada."
What pathologies does Stereotactic Body Radiotherapy typically target?
"Stereotactic Body Radiotherapy is commonly used to address the spread of incurable stage iii non-small cell lung cancer. It's also a viable option for those with untreated metastatic ureter urothelial carcinoma or advance directives."
Share this study with friends
Copy Link
Messenger